GENMAB AS/ DK0010272202 /
06/06/2024 09:05:05 | Chg. -4.40 | Volume | Bid13:22:12 | Ask13:22:12 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
260.60EUR | -1.66% | 0 Turnover: - |
259.60Bid Size: 36 | 262.40Ask Size: 36 | 17.24 bill.EUR | - | - |
GlobeNewswire
30/04
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03/04
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
17/10/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
25/09/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
04/09/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
09/11/2021
BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
GlobeNewswire
19/10/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
20/09/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
09/08/2021
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
GlobeNewswire
21/07/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021